Investors are overlooking healthcare stocks and should consider these top picks, says JPMorgan

Investors have been shying away from healthcare stocks lately, but according to JPMorgan, this could be a missed opportunity. The bank's analysts have identified several top picks in the sector that they believe are worth considering. These include Eli Lilly, AbbVie, and Danaher Corporation, all of which have strong fundamentals and growth potential.

The healthcare sector has faced some headwinds recently, including regulatory uncertainty and pricing pressure. However, JPMorgan's analysts believe that some stocks have been overly punished and now offer attractive valuations. Eli Lilly, for example, has a strong pipeline of new products and a solid track record of execution. AbbVie, meanwhile, has a diversified portfolio of pharmaceuticals and a history of successful acquisitions. Danaher Corporation, a life sciences company, has a strong track record of growth and a solid balance sheet.

For options traders, the key thing to watch is how these stocks respond to upcoming catalysts, such as earnings reports and FDA decisions. Will Eli Lilly's new product launches meet expectations? Can AbbVie continue to deliver growth through its acquisitions? And how will Danaher Corporation's life sciences business perform in the face of economic uncertainty? As always, it's essential to do your own research and consider your own risk tolerance before making any investment decisions. Keep an eye on these stocks and their volatility levels to determine if they align with your options trading strategy.

Originally reported by marketwatch.com. OptionNews adds analysis for finance & markets readers.